Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606268 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00606268 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 42 participants.
The verdict
NCT00606268, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal prophylaxis in children and adolescents undergoing HSCT
Interventions
- DRUG Micafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606268
The ClinicalTrials.gov registry entry for NCT00606268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Micafungin is the first listed.
NCT00606268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606268 about?
NCT00606268 is a clinical study titled "A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant". The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal prophylaxis in children and adolescents undergoing HSCT
What is the current status of trial NCT00606268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2007-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00606268?
The interventions under investigation include: Micafungin (DRUG).
Who is sponsoring clinical trial NCT00606268?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.